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Abstracts / Biol Blood Marrow Transplant 19 (2013) S109eS128S110was reduced to 22% for grade 2-4 acute GVHD (only 4%: grade
3-4) with no increase in relapse (17% at 1-year).
Conclusions: These data demonstrate translation of our
experimental observations into a novel proof-of-concept
phase I/II clinical trial of vorinostat in reducing the incidence
of GVHD.3
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Using methods to inhibit the NFkB family member c-Rel,
a transcription factor that upon antigen receptor triggering
regulates lymphocyte survival and proliferation, we devel-
oped a novel strategy to diminish alloactivation of T cells
while preserving GVT activity.
We investigated the role of c-Rel during GVHD in MHC
mismatched as well as MHC matched, minor antigen mis-
matched murine HSCT models. c-Rel-/- T cells caused signif-
icantly less GVHD than normal T cells, as determined by
survival (p<0.001), clinical GVHD score (p<0.01), and
histopathology of GVHD target organs. On day 3 post trans-
plant, proliferation and activation of c-Rel-/- T cells was
impaired (p<0.001 CFSElow/high ratio; p<0.01 CD25þ donor
cells) and pSTAT5 expression was decreased (p<0.05),
resulting in less expansion of donor derived effector Tcells by
day 7 after transplant (p<0.001). Unexpectedly, serum levels
of IL-2 were increased on day 7, likely secondary to decreased
pSTAT5-mediated negative feed back on IL-2 secretion. In
addition, IL-21, a target gene of c-Rel and negative regulator
of IL-2, was decreased (p<0.05) in recipients of c-Rel-/- T cells
during early GVHD. By day 14 post BMT we observed
increased numbers of donor derived Tregs with increased
CD25 expression in recipients of c-Rel-/- T cells (p<0.05),
suggesting that the increased IL-2 levels primarily beneﬁted
the expansion of Tregs. Consistent with this hypothesis, in
vivo depletion of donor Tregs in recipients of c-Rel inhibited
Foxp3DTR transgenic T cells exacerbated GVHD.
We next evaluated if c-Rel deﬁcient T cells were able to
mediate antitumor activity. We challenged allogeneic HSCT
recipients with either a liquid tumor (A20) or a solid tumor
(RENCA) and found that GVT activity in c-Rel-/- T cells
recipients was intact in the absence of GVHD, resulting in
signiﬁcantly improved survival compared to recipients of
wildtype T cells (p<0.001 A20; p<0.01 RENCA). Using
syngeneic GVT models with EL4 as well as B16 we could
demonstrate strong anti-tumor activity of c-Rel deﬁcient
polyclonal T cells targeting EL4 as well as melanoma antigen-
speciﬁc pmel-1 transgenic T cells in the absence of T cell
alloactivation, reinforcing the notion of separation of GVHD
from GVT activity through inhibition of c-Rel signaling.
The potential for clinical translation of our approach is
highlighted by a series of experiments testing the efﬁcacy of
a recently developed Pyrimidinetrione-based small molecule
c-Rel inhibitor compound. Using T cells that were pre-incubated with this c-Rel inhibitor, we reproduced our above
described effects on GVHD and antitumor activity (Figure 1).
Taken together, our ﬁndings identify c-Rel as a promising
target for the development of a clinical strategy to prevent
GVHD while preserving GVT activity, and to possibly even
enable adoptive T cell therapy across MHC barriers that
would be incompatible with a conventional transplant
approach.
Figure 1. Pre-incubation of donor T cells with a c-Rel antagonist prevents
GVHD while preserving GVT activity.
(A-C) Lethally irradiated (8.5Gy) BALB/c recipients received 5  106 WT B6
TCD-BM cells with 0.5  106 WT B6 CD5+ T cells after 24 hours of pre-
incubation with a c-Rel antagonist. Control mice received 5  106 WT B6 TCD-
BM cells with 0.5  106 WT B6 CD5+ T cells that were pre-incubated with
empty vehicle control solution. On day 0, HSCT recipients were challenged
with 0.25  106 luciferase-expressing A20-TGL tumor cells. Data are repre-
sentative of at least two independent experiments; n ¼ 5-8. Error bars indicate
SEM. *P<0.05; ***P<0.001. (A) Survival curve. (B) Body weight changes. (C)
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Historical data are conﬂicting as to whether superior
outcomesoccurwith cyclophosphamide (CY)þTBI compared
to oral busulfan (BU)-based myeloablative conditioning
regimens. IV BUwith orwithout pharmacokineticmonitoring
is better tolerated than oral BU. To testwhethermyeloablative
IVBU-basedconditioning regimens result in similaroutcomes
to traditional TBI-based conditioning, we conducted
a prospective multi-center cohort study comparing these 2
approaches in patients with myeloid malignancies (AML,
MDS, CML) undergoing matched related or unrelated donor
blood or marrow transplants. All patients received myeloa-
blative conditioning intensity (IV BU (>9mg/kg) plus Cy (60
mg/kg) or ﬂudarabine (80mg/m2); TBI (500cGy in a single
fraction or 800 cGy fractionated) plus Cy (60 mg/kg) or
etoposide (30 mg/kg)) and calcineurin-inhibitor based
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objective was to test the non-inferiority of overall survival
after IV BU compared to TBI. From March 2009 to February
2011,1,483eligiblepatientswereenrolled (IVBU,n¼1025, TBI,
n¼458) from 120 transplant centers. The 2 cohorts were
similar with respect to median age (45 years), gender (50%
female), race (88% Caucasian), performance status (68%90),
and HCT-CI. Most patients had acute myeloid leukemia (68%
BU, 78% TBI). Disease status was early (51%), intermediate
(18%) and advanced (31%) andwere balanced in both cohorts.
Grafts were primarily PB (77%) frommatched sibling (40%) or
well-matched unrelated donors (48%), balanced in both
cohorts. IVBUregimenswereCY (59%) or Flu (41%) based. 2-yr
probabilities of overall survival (95% CI), were 56% (53-60%)
and 48% (43-54%) for IV BU and TBI, respectively (p¼0.02).
Corresponding probabilities of progression-free survival
(PFS) were 49% (45-52%) and 44% (40-49%), (p¼0.17). The
incidence of hepatic veno-occlusive disease (VOD)/sinusoidal
obstruction syndrome (SOS)was5% forBUand1% for TBI; (p<
0.001). Outcomes were the same for BUþCY and BUþFlu
regimens. There were no differences in engraftment of
neutrophils or platelets, disease relapse, grade 2-4 acute or
chronic GVHD. Multivariate Analysis (MVA) (adjusting for
HCT-CI, disease andstatus, donor type, age, PS, and race) of the
main outcomes is summarized in Table. Compared to TBI, IV
BU was associated with superior survival and no increased
risk of relapse or TRM. These results support the use of mye-
loablative BU- over TBI-based conditioning regimens for
treatment of AML, MDS, and CML.
Table
Cox Proportional Hazards MVA for IV BU vs. TBI
Outcome N IV BU vs. TBI
HR (95% CI)
P-value
OM 1439 0.82 (0.68-0.98) 0.026
TRM 1434 0.81 (0.61-1.08) 0.15
Rel 1434 0.93 (0.76-1.12) 0.43
TF 1434 0.90 (0.77-1.06) 0.19
HR indicats hazard ratio; N, number of subjects; OM, overall mortality; Rel,
relapse; TF, treatment failure, relapse or death; TRM, treatment-related5
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We have previously demonstrated that small numbers of
ex vivo-expanded, trivirus-speciﬁc Tcells targeting EBV, CMV,
and Adv are safe, effective and protective in vivo. However,
broader implementation is limited by the need for infectious
virus/vector, and prolonged (8-12wks) and complex manu-
facture, while antigenic competition limits extension to
additional viruses. We now evaluate whether T-cell lines
manufactured using methods that exclude viral components
and utilize simpliﬁed manufacturing technology can be clin-
ically effective. With NHLBI-PACT support, 29 clinical-grade
rCTL lines have beengenerated. Froman initial 15x106 PBMCs,
mortality.we prepared a median of 21488x106 T-cells (range 100-
420x106) over 9-11 days using DCs nucleofected with DNA
plasmids encoding immunogenic EBV (LMP2, EBNA1 and
BZLF1), Adv (Hexon and Penton), and CMV (pp65 and IE1)
antigens, and expansion with IL4þ7 in G-Rex devices. The
rCTL lines were polyclonal, comprising both CD4þ (333%)
and CD8þ (60.53%) cells, that expressed activation and
memory markers. Twenty lines generated from donors that
wereseropositive for all virusesdemonstratedactivityagainst
all 3 targets - CMV (IE1: 359100; pp65: 637177SFC/2x105),
EBV (LMP2: 21760, EBNA1: 6719 and BZLF1: 11131) and
Adv (Hexon: 26574, Penton: 19153) - while 9 lines
generated from CMV seronegative donors demonstrated
activity exclusively against EBV (LMP2: 19770, EBNA1:
14551 and BZLF1: 23984) and Adv (Hexon: 27196, Pen-
ton: 25490). None of the T-cell lines reacted against
unmodiﬁed recipient cells. To date we have administered
these lines to 10 allogeneic HSCT recipients at doses ranging
from 0.5-2x107/m2 as treatment for CMV (n¼3), Adv (n¼2),
EBV (n¼2), EBVþAdv (n¼1), and CMVþAdv (n¼2). One
patient developed a skin rash 2weeks post-rCTLs but no other
toxicity have been observed. Eight treated patients, including
one with a biopsy-proven EBV lymphoma and the 3 patients
with double reactivations, had complete clinical responses to
rCTL, which corresponded with an increase in the frequency
of virus-speciﬁc T-cells detected in peripheral blood. For CMV
we saw an increase from a median of 0.5 to 96 and 1 to 277
SFC/4x105 IE1 and pp65-speciﬁc T cells, respectively 3-6wks
post-infusion; for Adv an increase from mean 0.5 to 137 and
0.5 to 99 SFC/4x105 Hexon and Penton-speciﬁc cells, respec-
tively, and for EBV an increase from 2.8 to 227,1.5 to 39, and 1
to 188.5 SFC/4x105 EBNA1, LMP2, and BZLF1-speciﬁc T-cells,
respectively. Twopatients failed to respond to rCTLs; onewith
a 3 year history of persistent CMV colitis and one with
elevated EBV DNA; both had high pre-existing virus-speciﬁc
T-cell precursors. rCTLs have been safe and effective in 80% of
treated patients and have the potential to increase the avail-
ability of cell products for HSCT recipients. We are currently
extending this platform to additional viruses.
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Idiopathic pneumonia syndrome (IPS) is a noninfectious
pulmonary disorder occurring acutely post-SCT, associated
